200 related articles for article (PubMed ID: 15861009)
61. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
62. Extracellular matrix remodeling following myocardial injury.
Lindsey ML; Mann DL; Entman ML; Spinale FG
Ann Med; 2003; 35(5):316-26. PubMed ID: 12952018
[TBL] [Abstract][Full Text] [Related]
63. Role of various proteases in cardiac remodeling and progression of heart failure.
Müller AL; Dhalla NS
Heart Fail Rev; 2012 May; 17(3):395-409. PubMed ID: 21739365
[TBL] [Abstract][Full Text] [Related]
64. Myocardial recovery from ischemia-reperfusion is compromised in the absence of tissue inhibitor of metalloproteinase 4.
Takawale A; Fan D; Basu R; Shen M; Parajuli N; Wang W; Wang X; Oudit GY; Kassiri Z
Circ Heart Fail; 2014 Jul; 7(4):652-62. PubMed ID: 24842912
[TBL] [Abstract][Full Text] [Related]
65. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
66. Extracellular matrix remodeling in hypertensive heart disease.
Shirwany A; Weber KT
J Am Coll Cardiol; 2006 Jul; 48(1):97-8. PubMed ID: 16814654
[No Abstract] [Full Text] [Related]
67. Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure.
Song YH; Cai H; Gu N; Qian CF; Cao SP; Zhao ZM
J Pharm Pharmacol; 2011 Apr; 63(4):541-9. PubMed ID: 21401606
[TBL] [Abstract][Full Text] [Related]
68. Metalloproteinase in myocardial adaptation and maladaptation.
Tyagi SC; Hoit BD
J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):241-6. PubMed ID: 12490970
[TBL] [Abstract][Full Text] [Related]
69. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies.
Takano H; Hasegawa H; Nagai T; Komuro I
Intern Med; 2003 Jun; 42(6):465-9. PubMed ID: 12857042
[TBL] [Abstract][Full Text] [Related]
70. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
Goetzenich A; Hatam N; Zernecke A; Weber C; Czarnotta T; Autschbach R; Christiansen S
J Heart Lung Transplant; 2009 Oct; 28(10):1087-93. PubMed ID: 19782292
[TBL] [Abstract][Full Text] [Related]
71. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
[TBL] [Abstract][Full Text] [Related]
72. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
Vanhoutte D; Heymans S
J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
[TBL] [Abstract][Full Text] [Related]
73. [Tumor necrosis factor alpha and myocardial matrix metalloproteinases in left ventricular remodeling].
Wang XM; Yang LX; Zhu SJ; Yang YJ; Guo CM; Qi F; Wei L; Shi YK; Wang Y; Ren L
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):828-31. PubMed ID: 15634542
[TBL] [Abstract][Full Text] [Related]
74. Novel approaches to retard ventricular remodeling in heart failure.
Spinale FG
Eur J Heart Fail; 1999 Mar; 1(1):17-23. PubMed ID: 10937974
[TBL] [Abstract][Full Text] [Related]
75. Understanding LV remodeling following myocardial infarction: are T1 maps by CMR the new guide?
Plein S; Kidambi A
JACC Cardiovasc Imaging; 2012 Sep; 5(9):894-6. PubMed ID: 22974801
[No Abstract] [Full Text] [Related]
76. Role of apoptosis in adverse ventricular remodeling.
Abbate A; Narula J
Heart Fail Clin; 2012 Jan; 8(1):79-86. PubMed ID: 22108728
[TBL] [Abstract][Full Text] [Related]
77. The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling.
Janicki JS; Brower GL; Gardner JD; Chancey AL; Stewart JA
Heart Fail Rev; 2004 Jan; 9(1):33-42. PubMed ID: 14739766
[TBL] [Abstract][Full Text] [Related]
78. Matrix matters.
Libby P; Lee RT
Circulation; 2000 Oct; 102(16):1874-6. PubMed ID: 11034930
[No Abstract] [Full Text] [Related]
79. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation.
Mukherjee R; Herron AR; Lowry AS; Stroud RE; Stroud MR; Wharton JM; Ikonomidis JS; Crumbley AJ; Spinale FG; Gold MR
Am J Cardiol; 2006 Feb; 97(4):532-7. PubMed ID: 16461051
[TBL] [Abstract][Full Text] [Related]
80. Integrin expression during reverse remodeling in the myocardium of heart failure patients.
Dullens HF; Schipper ME; van Kuik J; Sohns W; Scheenstra M; van Wichen DF; Van Oosterhout MF; de Jonge N; de Weger RA
Cardiovasc Pathol; 2012; 21(4):291-8. PubMed ID: 22100988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
